Skip to main content

Human Volunteers

5
Pipeline Programs
5
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
Nutritional BeveragePhase 21 trial
Active Trials
NCT01464385Completed121Est. Dec 2011
Pfizer
PfizerNEW YORK, NY
3 programs
3
BMN 673Phase 13 trials
PF-04937319 / ketoconazolePhase 1Small Molecule1 trial
Simvastatin/PF-03882845Phase 11 trial
Active Trials
NCT02034916Terminated84Est. Oct 2018
NCT01945775Completed431Est. Mar 2021
NCT01776437Completed18Est. Jul 2013
+2 more trials
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
MVA-NP+M1Phase 1
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
LevetiracetamPHASE_11 trial
LevetiracetamPHASE_11 trial
Active Trials
NCT01618903Completed24Est. Jul 2012
NCT01618877Completed24Est. Jul 2012
Oxford BioTherapeutics
1 program
MVA-NP+M1PHASE_11 trial
Active Trials
NCT03277456Completed6Est. Nov 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerBMN 673
PfizerBMN 673
AbbottNutritional Beverage
Oxford BioTherapeuticsMVA-NP+M1
PfizerBMN 673
UCB PharmaLevetiracetam
UCB PharmaLevetiracetam
PfizerPF-04937319 / ketoconazole
PfizerSimvastatin/PF-03882845

Clinical Trials (9)

Total enrollment: 732 patients across 9 trials

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Start: Oct 2013Est. completion: Mar 2021431 patients
Phase 3Completed

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Start: Dec 2013Est. completion: Oct 201884 patients
Phase 2Terminated
NCT01464385AbbottNutritional Beverage

Nutrition Beverage Tolerance Study

Start: Oct 2011Est. completion: Dec 2011121 patients
Phase 2Completed

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

Start: Sep 2017Est. completion: Nov 20176 patients
Phase 1Completed

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Start: Feb 2013Est. completion: Jul 201318 patients
Phase 1Completed

An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese

Start: May 2012Est. completion: Jul 201224 patients
Phase 1Completed

A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers

Start: May 2012Est. completion: Jul 201224 patients
Phase 1Completed
NCT01468714PfizerPF-04937319 / ketoconazole

A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects

Start: Oct 2011Est. completion: Oct 201110 patients
Phase 1Completed
NCT01445860PfizerSimvastatin/PF-03882845

Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics

Start: Aug 2011Est. completion: Sep 201114 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.